Published in Antimicrob Agents Chemother on September 01, 2004
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci (2010) 1.78
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Antiviral resistance and hepatitis B therapy. Hepatology (2009) 1.67
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother (2006) 1.45
Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Inhibition of hepatitis B virus polymerase by entecavir. J Virol (2007) 1.32
A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother (2007) 1.27
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol (2006) 1.16
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother (2007) 1.14
Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci (2013) 1.09
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol (2010) 1.07
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06
Review of hepatitis B therapeutics. Clin Infect Dis (2010) 1.06
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One (2013) 1.01
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J (2011) 1.00
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem (2008) 0.99
Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist (2011) 0.99
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep (2011) 0.99
Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci (2011) 0.98
Potential Use of Plectranthus amboinicus in the Treatment of Rheumatoid Arthritis. Evid Based Complement Alternat Med (2007) 0.97
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol (2013) 0.94
Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol (2010) 0.93
Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses (2010) 0.93
Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci (2011) 0.93
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol (2014) 0.93
Update on hepatitis B virus infection. World J Gastroenterol (2014) 0.93
Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study. Dig Dis Sci (2013) 0.92
Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol (2009) 0.92
Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol (2011) 0.92
Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res (2008) 0.92
Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology (2009) 0.92
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol (2012) 0.89
SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol (2014) 0.89
The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag (2007) 0.88
Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem (2011) 0.87
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther (2013) 0.87
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine. Antimicrob Agents Chemother (2006) 0.87
Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci (2007) 0.86
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One (2010) 0.86
Current and future directions for treating hepatitis B virus infection. World J Hepatol (2015) 0.85
Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag (2009) 0.84
A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. J Virol (2015) 0.84
Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. J Gastroenterol (2007) 0.84
Molecular diagnosis of entecavir resistance. Hepat Mon (2010) 0.84
Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies. Hepat Mon (2011) 0.84
Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach. World J Gastroenterol (2013) 0.84
Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int (2007) 0.83
Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am (2010) 0.82
Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci (2005) 0.81
Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicians (2012) 0.81
Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol (2008) 0.81
The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice. Evid Based Complement Alternat Med (2008) 0.81
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol (2012) 0.81
Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int (2007) 0.81
Management of chronic hepatitis B patients: efficacy & limitation of nucleos(t)ide analogues. Indian J Med Res (2011) 0.80
Novel approaches towards conquering hepatitis B virus infection. World J Gastroenterol (2007) 0.80
Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol (2006) 0.80
Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int (2011) 0.80
Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver (2013) 0.80
Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells. World J Gastroenterol (2006) 0.80
Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med (2016) 0.79
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. Clin Mol Hepatol (2015) 0.79
Future directions in the treatment of HIV-HBV coinfection. HIV Ther (2009) 0.79
Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother (2009) 0.79
Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int (2008) 0.79
In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations. J Clin Microbiol (2007) 0.79
The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B. J Clin Transl Hepatol (2013) 0.78
Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive. World J Gastroenterol (2006) 0.78
Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro. Hepat Mon (2012) 0.78
Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. Exp Ther Med (2015) 0.78
Structurally similar woodchuck and human hepadnavirus core proteins have distinctly different temperature dependences of assembly. J Virol (2014) 0.78
Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci (2015) 0.78
Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro. BMC Complement Altern Med (2015) 0.78
Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. J Clin Microbiol (2014) 0.77
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol (2014) 0.77
High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus. J Clin Microbiol (2013) 0.77
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients. Med Sci Monit (2014) 0.77
Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy. J Clin Microbiol (2008) 0.77
Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells. World J Gastroenterol (2008) 0.77
A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int (2008) 0.77
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis (2011) 0.76
Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation. J Virol (2016) 0.76
The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol (2014) 0.76
Novel lamivudine resistance. Antimicrob Agents Chemother (2007) 0.75
Detection and analysis of resistance mutations of hepatitis B virus. Int J Clin Exp Med (2015) 0.75
Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) (2012) 0.75
Effects of two novel nucleoside analogues on different hepatitis B virus promoters. World J Gastroenterol (2008) 0.75
Hepatitis B virus infection. N Engl J Med (1997) 14.50
Viral hepatitis B. Lancet (2003) 4.86
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 4.14
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 2.80
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology (1998) 2.67
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 2.54
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol (2001) 2.14
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother (1997) 1.94
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol (2003) 1.87
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol (2003) 1.80
Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J Virol (1995) 1.77
The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol (1999) 1.69
Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol (1997) 1.56
Lamivudine therapy of WHV-infected woodchucks. Virology (1998) 1.52
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis (2001) 1.46
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother (2002) 1.45
In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother (1998) 1.36
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 1.32
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother (2002) 1.21
Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother (1999) 1.16
Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat (1999) 1.10
Generation of replication-competent hepatitis B virus nucleocapsids in insect cells. J Virol (1998) 1.06
Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol (2002) 0.97
Hepatitis B therapy: the plot thickens. Hepatology (1999) 0.96
Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs (2002) 0.89
Improved membrane filter method for fecal coliform analysis. Appl Microbiol (1975) 4.75
A unique RNA species involved in initiation of vesicular stomatitis virus RNA transcription in vitro. Cell (1976) 3.82
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol (1986) 3.59
Many rhinovirus serotypes share the same cellular receptor. J Virol (1984) 3.59
Vesicular stomatitis virus: mode of transcription. J Gen Virol (1977) 3.53
A correction in the nucleotide sequence of the Tn903 kanamycin resistance determinant in pUC4K. Nucleic Acids Res (1988) 3.47
In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14. J Virol (1985) 3.19
Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14. Proc Natl Acad Sci U S A (1985) 3.17
cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1989) 3.09
Complete nucleotide sequence of the leader RNA synthesized in vitro by vesicular stomatitis virus. Cell (1978) 3.06
A genetic approach to promoter recognition during trans induction of viral gene expression. Science (1986) 2.77
De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J Virol (2000) 2.65
The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. J Virol (1994) 2.61
Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol (1986) 2.54
The major and minor group receptor families contain all but one human rhinovirus serotype. Virology (1991) 2.50
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut (2010) 2.37
Relationship between the percentage of subgingival spirochetes and the severity of periodontal disease. J Periodontol (1982) 2.31
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Attitudes of patients towards the use of chaperones in primary care. Br J Gen Pract (2001) 2.19
Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16
A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100. Virology (1987) 2.10
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol (1995) 2.05
Herpes simplex virus VP16 rescues viral mRNA from destruction by the virion host shutoff function. EMBO J (1996) 1.99
Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem (1990) 1.99
A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis (2008) 1.98
Sequences flanking the centromere of human chromosome 10 are a complex patchwork of arm-specific sequences, stable duplications and unstable sequences with homologies to telomeric and other centromeric locations. Hum Mol Genet (1999) 1.94
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother (1997) 1.94
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A (1996) 1.93
Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. J Biol Chem (1993) 1.92
Intervening polyadenylate sequences in RNA transcripts of vesicular stomatitis virus. Cell (1978) 1.92
Interferon induction of fibroblast proteins with guanylate binding activity. J Biol Chem (1983) 1.87
Mapping and initiation studies on the leader RNA of vesicular stomatitis virus. Virology (1977) 1.78
Induction of unique mRNAs by human interferons. J Biol Chem (1982) 1.76
The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol (1995) 1.72
Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant (2001) 1.72
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Isolation of a receptor protein involved in attachment of human rhinoviruses. J Virol (1986) 1.68
Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol (2001) 1.68
Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade. J Virol (1986) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Heparin in acid solutions. Br Med J (1971) 1.65
Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology (2001) 1.65
Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology (1997) 1.64
Major histocompatibility complex-restricted antigen presentation to antigen-reactive T cells by B lymphocyte tumor cells. J Exp Med (1981) 1.60
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother (2000) 1.59
Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol (1997) 1.56
Bile duct injury during laparoscopic cholecystectomy: a report of the Standards Sub-committee of the Victorian State Committee of the Royal Australasian College of Surgeons. Aust N Z J Surg (1993) 1.53
Early detection of protein depletion in alcoholic cirrhosis: role of body composition analysis. Gastroenterology (1993) 1.52
In vitro synthesis of messenger RNA by a defective interfering particle of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1977) 1.51
Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo. J Gastroenterol Hepatol (2000) 1.49
Oncogenic re-wiring of cellular signaling pathways. Oncogene (2007) 1.48
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis (2001) 1.46
Structural organization of the hepatitis B virus minichromosome. J Mol Biol (2001) 1.45
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother (1998) 1.45
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother (2002) 1.45
Insertional inactivation of a gene which controls expression of vancomycin resistance on plasmid pHKK100. FEMS Microbiol Lett (1992) 1.42
The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids. J Virol (1995) 1.41
Phenotype of the herpes simplex virus type 1 protease substrate ICP35 mutant virus. J Virol (1994) 1.41
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer (2011) 1.40
Telling the diagnosis to patients with Alzheimer's disease. Geriatricians' and psychiatrists' practice differs. BMJ (1997) 1.40
Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother (1992) 1.39
4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB. Bioorg Med Chem Lett (2000) 1.38
Long-term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled Type 1 diabetes. Diabetes Res Clin Pract (2010) 1.38
Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli. J Virol (1989) 1.38
A cyclic AMP-responsive element-binding transcriptional activator in Drosophila melanogaster, dCREB-A, is a member of the leucine zipper family. Mol Cell Biol (1992) 1.37
In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother (1998) 1.36
Human-murine chimeras of ICAM-1 identify amino acid residues critical for rhinovirus and antibody binding. J Virol (1991) 1.36
Polymorphisms of Helicobacter pylori HP0638 reflect geographic origin and correlate with cagA status. J Clin Microbiol (2002) 1.35
Use of statins. Sheffield tables have shortcomings. BMJ (1997) 1.35
Cell surface receptors for picornaviruses. Bioessays (1986) 1.35
Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther (1999) 1.34
Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci U S A (1989) 1.34
Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression. Hepatology (1996) 1.32
OT-CLL: a human T cell chronic lymphocytic leukemia that produces IL 2 in high titer. J Immunol (1982) 1.32
Identification of a native Dichelobacter nodosus plasmid and implications for the evolution of the vap regions. Gene (1996) 1.32
Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother (1999) 1.27
Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis (1994) 1.27
Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. Proc Natl Acad Sci U S A (1994) 1.27
Detoxification of 1,024 alcoholic patients without psychoactive drugs. JAMA (1978) 1.26
Characterization of protease cleavage sites involved in the formation of the envelope glycoprotein and three non-structural proteins of dengue virus type 2, New Guinea C strain. J Gen Virol (1987) 1.26
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother (2000) 1.26
Evolution of rabbit haemorrhagic disease virus (RHDV) in the European rabbit (Oryctolagus cuniculus) from the Iberian Peninsula. Vet Microbiol (2008) 1.25
Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol (1995) 1.24
Methylation of messenger RNA of Newcastle disease virus in vitro by a virion-associated enzyme. Proc Natl Acad Sci U S A (1975) 1.24
Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat (2006) 1.20
Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses. Virology (1985) 1.20
Lower esophageal sphincter response to gastric alkalinization. A new mechanism for treatment of heartburn with antacids. Ann Intern Med (1971) 1.19
Nucleotide sequence of the leader RNA of the New Jersey serotype of vesicular stomatitis virus. Nucleic Acids Res (1978) 1.18
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother (2001) 1.18
In vitro activity of the herpes simplex virus type 1 protease with peptide substrates. J Biol Chem (1993) 1.18
Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. J Biol Chem (1994) 1.17
Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor. J Virol (1990) 1.17
Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother (2001) 1.16
Chimeric picornavirus polyproteins demonstrate a common 3C proteinase substrate specificity. J Virol (1989) 1.15